1. Home
  2. SKYE vs JDZG Comparison

SKYE vs JDZG Comparison

Compare SKYE & JDZG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Skye Bioscience Inc.

SKYE

Skye Bioscience Inc.

HOLD

Current Price

$1.01

Market Cap

44.9M

Sector

Health Care

ML Signal

HOLD

JDZG

JIADE LIMITED

HOLD

Current Price

$1.50

Market Cap

42.5M

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
SKYE
JDZG
Founded
2012
2020
Country
United States
China
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Other Consumer Services
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
44.9M
42.5M
IPO Year
N/A
2024

Fundamental Metrics

Financial Performance
Metric
SKYE
JDZG
Price
$1.01
$1.50
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
$14.75
N/A
AVG Volume (30 Days)
431.9K
413.9K
Earning Date
03-19-2026
12-17-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$2,680,742.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
13.19
52 Week Low
$0.68
$0.73
52 Week High
$5.75
$7.92

Technical Indicators

Market Signals
Indicator
SKYE
JDZG
Relative Strength Index (RSI) 50.53 59.41
Support Level $0.95 $1.34
Resistance Level $1.07 $1.85
Average True Range (ATR) 0.08 0.29
MACD 0.02 0.07
Stochastic Oscillator 45.80 70.52

Price Performance

Historical Comparison
SKYE
JDZG

About SKYE Skye Bioscience Inc.

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

About JDZG JIADE LIMITED

Jiade Ltd specializes in providing one-stop comprehensive education supporting services to adult education institutions, through a wide range of software platform and auxiliary solutions. Auxiliary solutions encompass exam administration services and teaching support services throughout the entire teaching cycle. Specifically, the company offers pre-enrollment guidance on school/major selection and application strategy development, training for entrance exams, and assistance in the application process. The company also provides offline tutoring, exam administration services, guidance on graduation thesis, and social practice assistance included in the one-stop comprehensive education supporting services in the People's Republic of China.

Share on Social Networks: